Reneo Pharmaceuticals Announces Board and Executive Changes
Ticker: OKUR · Form: 8-K · Filed: Sep 13, 2024 · CIK: 1637715
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
Reneo Pharma shakes up board & exec pay. Big changes coming?
AI Summary
Reneo Pharmaceuticals, Inc. announced on September 9, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, along with the election of new directors and adjustments to compensatory arrangements for its officers.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's future direction and stability.
Key Numbers
- 001-40315 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-2309515 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Reneo Pharmaceuticals, Inc. (company) — Registrant
- September 9, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 18575 Jamboree Road, Suite 275-S, Irvine, California 92612 (address) — Principal Executive Offices
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates departures of certain officers and directors but does not specify the exact roles in this summary.
Who are the newly elected directors?
The filing mentions the election of new directors but does not name them in this section.
What are the details of the compensatory arrangements for the officers?
The filing notes changes to compensatory arrangements for certain officers but does not provide specific details in this summary.
What is the primary business of Reneo Pharmaceuticals, Inc.?
Reneo Pharmaceuticals, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
When was this 8-K filing submitted?
This 8-K filing was submitted on September 13, 2024.
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-09-13 16:21:52
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share RPHM The Nasdaq Stock Mar
Filing Documents
- d809509d8k.htm (8-K) — 23KB
- 0001193125-24-218879.txt ( ) — 145KB
- rphm-20240909.xsd (EX-101.SCH) — 3KB
- rphm-20240909_lab.xml (EX-101.LAB) — 18KB
- rphm-20240909_pre.xml (EX-101.PRE) — 11KB
- d809509d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Reneo Pharmaceuticals, Inc. Date: September 13, 2024 By: /s/ Gregory J. Flesher Gregory J. Flesher President and Chief Executive Officer (Principal Executive Officer)